Price
No data yet.
Social Signal Score
Analyst Ratings
18 analystsRevenue
$862.68M+188.93%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Chirag K. Patel
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 8,700
- Beta
- 1.21
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 1.96
Financials
Revenue
$862.68M+188.9%Net Income
$-7.46M-113.8%EBITDA
$127.23M+24.7%Free Cash Flow
$60.70M+1074.7%EPS (diluted)
$-0.06-120.7%Shares Outstanding (diluted)
335.73M+77.6%Operating Expenses
$208.02MCash & Debt
$157.40MReturn of Capital
$0.00Revenue by Segment (annual)
$528.51MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $3.02B | $72.06M | $0.23 |
| 2024 | $2.79B | $-116.89M | $-0.38 |
| 2023 | $2.39B | $-83.99M | $-0.48 |
| 2022 | $2.21B | $-129.99M | $-0.86 |
| 2021 | $2.09B | $10.62M | $0.07 |
| 2020 | $1.99B | $91.06M | $0.61 |
| 2019 | $1.63B | $-361.92M | $-4.57 |
| 2018 | $1.66B | $-169.73M | $-1.33 |
| 2017 | $1.03B | $167.65M | $1.46 |
| 2016 | $1.02B | $207.38M | $1.10 |
| 2015 | $866.28M | $169.45M | $0.90 |
| 2014 | $785.62M | $176.93M | $0.94 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from AMRX's reported EPS growth of -12.0% a year over 11 years.
- EPS in 5 years
- $0.12
- Implied price
- $6.67
- Return from $21.12
- -20.6% a year
To earn 15.0% a year on these assumptions you'd need to buy at $3.32 — -84.3% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 39 | 47 | 55 | 63 | 71 |
|---|---|---|---|---|---|
| -22.0% | -34.3% | -31.8% | -29.6% | -27.7% | -25.9% |
| -17.0% | -30.1% | -27.4% | -25.1% | -23.0% | -21.2% |
| -12.0% | -25.9% | -23.0% | -20.6% | -18.4% | -16.4% |
| -7.0% | -21.6% | -18.7% | -16.1% | -13.8% | -11.7% |
| -2.0% | -17.4% | -14.3% | -11.6% | -9.1% | -6.9% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50-28.57%Social Signal Score
Mentions (22)
- News (RSS)investing·4d ago·Neutral
Amneal Pharmaceuticals stock hits 52-week high at 22.07 USD
View source ↗ - Newsseekingalpha.com·5d ago·Neutral
Amneal: Buy More After Impressive Q3 Results, As Active Drug Pipeline Keeps Growing Amneal Pharmaceuticals gets a buy reaffirmed, despite its sharp rally, supported by a robust pipeline, niche demand, improving margins, and projected upside. Amneal delivered a fourth consecutive earnings beat, with Q3 revenue up 10% and higher FY26 revenue guidance. Kashiv integration and biosimilars offer growth potential, while positive operating cash flow and an improving operating margin support earnings qua…
View source ↗ - News (Marketaux)rttnews.com·9d ago·Positive
Show Me The Money: After A 120% Rally, Amneal (AMRX) Positions For Its Next Growth Chapter In 2027 Shares of Amneal Pharmaceut[+308 characters]
View source ↗ - Newszacks.com·18d ago·Positive
AMRX Q3 Earnings & Sales Beat Estimates, FY'26 Guidance Raised Amneal tops Q3 estimates as strong Affordable Medicines and Specialty growth drives higher 2026 guidance and boosts its growth outlook.
View source ↗ - Newsseekingalpha.com·19d ago·Positive
Amneal Pharmaceuticals, Inc. (AMRX) Q3 2026 Earnings Call Transcript Amneal Pharmaceuticals, Inc. (AMRX) Q3 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·19d ago·Neutral
What Amneal Pharmaceuticals (AMRX) Said on Its Q3 Earnings Call Amneal Pharmaceuticals NASDAQ: AMRX reported third-quarter 2026 revenue of $863 million, up 10% from a year earlier, as growth in affordable medicines and specialty products more than offset an expected decline at its AvKARE business. Adjusted EBITDA rose 30% to $207 million, while adjusted earnings per share increased 53% to $0.26.
View source ↗ - Newszacks.com·19d ago·Positive
Amneal Pharmaceuticals (AMRX) Q3 Earnings and Revenues Top Estimates Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.17 per share a year ago.
View source ↗ - Newsglobenewswire.com·19d ago·Negative
Amneal Reports Third Quarter 2026 Financial Results – Q3 2026 Net Revenue of $863 million ; GAAP Net Loss of $22 million ; Diluted Loss per Share of $(0.06) – – Adjusted EBITDA of $207 million ; Adjusted Diluted EPS of $0.26 – – Updating 2026 Full Year Guidance –
View source ↗ - Newszacks.com·26d ago·Neutral
Implied Volatility Surging for Amneal Pharmaceuticals Stock Options Investors need to pay close attention to AMRX stock based on the movements in the options market lately.
View source ↗ - Newszacks.com·27d ago·Neutral
Will Amneal (AMRX) Beat Estimates Again in Its Next Earnings Report? Amneal (AMRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
View source ↗ - News (Marketaux)gurufocus.com·38d ago·Positive
Amneal Pharmaceuticals Inc (AMRX) Shares Fall 3.4% -- GF Value Says Still Overvalued On October 14, 2026, Amneal <em[+273 characters]
View source ↗ - Newsglobenewswire.com·45d ago·Neutral
Amneal to Report Third Quarter 2026 Results on November 3, 2026 BRIDGEWATER, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), today announced it will report third quarter 2026 financial results on Tuesday, November 3, 2026, before market open. The Company will host an audio webcast at 8:30 a.m. ET.
View source ↗ - News (RSS)zerohedge·62d ago·Neutral
…as 25% after the healthcare software company cut its revenue guidance for FY27 amid disruption caused by a cyber security incident. Ipsen drops as much as 7.8% after Amneal Pharmaceuticals received FDA approval for its generic version of somatuline. Asian stocks advanced as an extended rally in semiconductor shares and a decline in oil prices supported investor sentiment. The MSCI Asia Pacific Index rose more than 1%, heading for a fourth straight session of gains. Samsung Electronics, TSMC and …
View source ↗ - Newsglobenewswire.com·65d ago·Positive
Amneal Announces FDA Approval and Launch of Lanreotide Injection - Expands complex injectables portfolio with important long-acting oncology treatment - Immediate commercial launch supported by in-house production
View source ↗ - Newszacks.com·66d ago·Positive
Amneal (AMRX) Surges 8.6%: Is This an Indication of Further Gains? Amneal (AMRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
View source ↗ - News (RSS)yahoo·79d ago·Neutral
Amneal Pharmaceuticals (AMRX) Bets Big On Biosimilars While Wall Street Retreats
View source ↗ - Newszacks.com·87d ago·Positive
5 Defensive Stocks to Buy as Consumer Confidence Hits 7-Month Low COCO, DAR, CNC, EXC and AMRX offer a defensive appeal as consumer confidence hits a 7-month low amid inflation and labor market concerns.
View source ↗ - Newszacks.com·94d ago·Neutral
4 Healthcare Stocks to Safeguard Your Portfolio as Fed Plans Rate Hike A rate hike could keep markets volatile, making BVS, CNC, AMRX and CRON healthcare stocks to consider as inflation stays elevated.
View source ↗ - Newszacks.com·96d ago·Neutral
5 Top-Ranked High-Efficiency Stocks Poised for Stronger Returns Five stocks, including CareDx and Caterpillar, cleared an efficiency screen based on key ratios exceeding industry averages.
View source ↗ - Newszacks.com·102d ago·Positive
Is AMRX Stock a Buy as Growth Improves but Execution Risks Persist? Amneal enters the second half of 2026 with higher guidance and a broader pipeline, but Rytary erosion and execution risks raise the stakes.
View source ↗ - Newszacks.com·102d ago·Positive
AMRX Stock Surges 44.8% in 3 Months: Can the Rally Keep Running Now? Amneal 44.8% rally faces a test as earnings, launches and pipeline progress contend with Rytary erosion and a higher historical valuation.
View source ↗ - Newszacks.com·103d ago·Positive
Amneal (AMRX) Is a Great Choice for 'Trend' Investors, Here's Why Amneal (AMRX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
View source ↗
Earnings
Fri, Feb 26(in 3 months)
Consensus estimate $0.24 per share
Typical surprise +34.8% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Nov 3$0.26 vs $0.24beat
- Thu, Jul 30$0.30 vs $0.22beat
- Thu, May 7$0.27 vs $0.17beat
- Fri, Feb 27$0.21 vs $0.18beat
- Thu, Oct 30$0.17 vs $0.13beat
- Tue, Aug 5$0.25 vs $0.18beat
Estimates and results for AMRX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by AMRX officers and directors.
- Bought
- —
- Sold
- $7.7m
0 trades
5 trades
- Kiely Johnsold
- Shah Nikitasold
- Daly Jason B.sold
- Daly Jason B.sold
- Autor Deborah M.sold
95 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Gilbert Cisneroshouse · CA39 · disclosed Jun 18, 2019 (20d later)Sell$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Jun 15, 2019 (22d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
